Aterovax's leading product AteroDX ISO® is developped

Aterovax licenses sPLA2 cardiovascular disease risk test to Zeus Scientific

Corporate overview

Aterovax is an in vitro diagnostic (IVD) company that develops innovative solutions to predict, diagnose and prevent cardiovascular disease through its Unique understanding of atherosclerosis.


Our leading diagnostic product AteroDx ISO®, is now available. The test detetermines the concentration of the sPLA2 enzyme, which has been validated as a potent biomarker of the vulnerable or destabilised atherosclerotic plaque.

Scientific evidence

sPLA2 is a powerful cardiovascular biomarker which has been evaluated through many clinical studies, including 10,000 patients. A bibliography is available here.